Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt.

The Moderna Laboratory has begun the so-called phase 1 trial stage of an HIV vaccine using messenger RNA technology in the United States, on 56 uninfected adults, both the biotech company and the ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the past decade. Despite underperforming the market in recent years, Pfizer could ...

According to insiders at IAVI, the International AIDS Vaccine Initiative (IAVI), a U.S. Department of Defense contractor, is ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox infection.

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of ...

Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was ...

In the final days of President Joe Biden’s term, Moderna MRNA won the $590 million contract to use its mRNA vaccine technology for a bird-flu vaccine. Back To Top ...